Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited
MNC (JVs and subsidiaries)
Industry Pharmaceutical
Founded 1983
Headquarters Hinjwadi, Pune, India
Key people
 Satish Mehta[1] CEO
Products tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products
US$220 million
Number of employees
 9000+
Website www.emcure.com

Emcure Pharmaceuticals, headquartered at Pune in West India, is an Indian pharmaceutical company. The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Indian plants

  • Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
  • Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
  • Oncology injectable facility at Hinjawadi
  • Solid Orals facilities at Jammu and Bhosari
  • API facility at Kurkumbh- USFDA approved
  • Biotech facility at Hinjawadi
  • R&D center and upcoming plant at Ahmedabad

US plant

USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.

Capital markets

Emcure is planning to raise money through an initial public offering for some time now [2] In 2014, Blackstone sold its stake in Emcure to Bain Capital [3]

Recalls

In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus Anthracis, Penicillium Chrysogenum & E coli in some samples.[4] Teva recalled several batches of two products due to white tablets showing presence of Yersinia Pestis in 2011.[5]

AIDS Initiative

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [6] and Gilead Sciences for Tenofovir [7] as part of their Global Access Programs.

Anticancer portfolio

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[8] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9]

References

  1. ↑ http://investing.businessweek.com/businessweek/research/stocks/private/person.asp?personId=23350262&privcapId=21771338&previousCapId=671980&previousTitle=BLACKSTONE%20GROUP%20LP/THE
  2. ↑ http://www.moneycontrol.com/news/ipo-upcoming-issues/emcure-pharma-plans-rs-700-crore-ipo_534950.html
  3. ↑ http://archive.indianexpress.com/news/blackstone-to-sell-emcure-pharmaceuticals-stake-to-bain-capital/1209682/
  4. ↑ http://articles.economictimes.indiatimes.com/2010-11-11/news/27610085_1_pfizer-american-drug-regulator-manufacturing-norms
  5. ↑ "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.
  6. ↑ http://www.business-standard.com/india/news/bristol-myers-outsources-aids-drug-to-emcure/233222/
  7. ↑ http://findarticles.com/p/news-articles/times-of-india-the/mi_8012/is_20060818/gilead-inks-offer-tenofovir/ai_n39427224/
  8. ↑ http://articles.economictimes.indiatimes.com/2012-03-02/news/31117087_1_emcure-pharmaceuticals-anti-hiv-drugs-emcure-signs-deal
  9. ↑ "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.